Goldman Sachs is out with a research report this morning, where it reiterates its Sell rating on Owens & Minor OMI; it has a $26.00 price target on the stock.
The GS analysts cited the company's recent earnings release, which was slightly better than expected. Despite that, the analysts believe the results do not suggest a meaningful pick-up in hospital utilization.
Despite recent top-line growth, the company maintained its 2011 guidance for 3%-5% revenue growth, which they believe could prove challenging given the lack of definitive signs of improvement in underlying demand.
In light of competitor Cardinal Health's commentary around "sluggish" in-patient procedure volumes, the analysts still consider the current utilization picture to be a headwind for OMI.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in